Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission.

Non GAAP Measures

This press release contains financial measures not prepared in accordance with US GAAP.)These measures are referred to as "Non GAAP" measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effectivetax rate on Non GAAP income before income taxes and earnings of equity method investees ("Effective tax rate on Non GAAP income"); Non GAAP cost of product sales; Non GAAP research and development; Non GAAP selling, general and administrative; Non GAAP other income; Non GAAP cash generation; Non GAAP free cashflow and Non GAAP net debt. These Non GAAP measures exclude the effect of certain cash and non-cash items, that Shire's management believes are not related to the core performance of Shire's business.

These Non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of Shire's performance to historical results and to competitors' results.)Shire's Remuneration Committee uses certain key Non GAAP measures when assessing the performance and compensation of employees, including Shire's executive directors.

The Non GAAP measures are presented in this press release as Shire's management believe that they will provide investors with a means of evaluating, and an understanding of how Shire's management evaluates, Shire's performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many non-recurring, infrequent or non-cash items that Shire's management believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.

These Non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepa
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... March 9 -12, at the Ernest N. Morial ... 919 exhibitors (count as of February 19, 2015) ... community in industrial, academic, and government labs. The ... such as, but not limited to, analytical chemistry; ...
(Date:2/26/2015)... Innovation is more urgent than ... parts of the world and transforming global markets ... manufacturing to health care, disruption is constantly underway. ... socio-political trends shake the foundations of established business ... CEOs to survive the next wave of mega-change. ...
(Date:2/26/2015)... According to a new market report published by ... (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled Products and ... and Forecast, 2013 – 2019,”the global agricultural biotechnology market ... is expected to reach USD 28,694.1 million by 2019, ... 2019. , Demand for food production has increased ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2
... , , , ... AMGN ) today announced detailed results from a Phase ... the treatment of bone metastases in 2,046 patients with advanced ... demonstrated superior efficacy compared to Zometa. These results were presented ...
... ... answer the question, "Is the Jatropha sector becoming a DotCom Bubble?". 2nd JatrophaWorld ... Viridesco Ltd. will discuss the challenges, controversies & paradoxes of the nascent Jatropha non-food ... ...
... has become just another fixture, it,s time to take a ... used to develop paper-based biosensors that can detect certain harmful ... bioterrorism agents. In a paper published in the July ... research team at McMaster University, working with the Sentinel Bioactive ...
Cached Biology Technology:Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 2Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 3Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 4Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 5Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 6Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 7Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 8Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 9Will Jatropha Become a 'DotCom Bubble' in Biofuel Industry? Leading to 2nd JatrophaWorld Africa, Jatropha Webinar on 30 Sept 09 Explores Challenges & Offers Strategies for Long-Term Success for This Non-Food Crop for Fuel 2Toxin detection as close as an inkjet printer 2
(Date:2/19/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ... "Military Electro-Optical / Infrared Systems Market by Type, ... Forecast to 2020" report to their offering. ... is expected to reach $16.35 billion by 2020, ... This report segments the military electro-optical/infrared systems market ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... April 2012 -- New techniques for identifying lung cancer ... nanotech ,nose, and a method to examine the cells ... presentations at the 3rd European Lung Cancer Conference (ELCC) ... is vital to improve lung cancer survival rates," commented ...
... new studies that may help doctors tailor lung cancer ... their tumors are being presented at the 3rd European ... of lung cancer treatment is to tailor the treatment ... Christie NHS Foundation Trust in Manchester, UK. "The studies ...
... Patients with advanced non-small cell lung cancer should only ... chemotherapy if their tumor is known to harbor EGFR ... Conference in Geneva, Switzerland. The results of ... that patients with unknown or negative mutation status should ...
Cached Biology News:Early detection techniques offer hope for improved outcomes in lung cancer patients 2Early detection techniques offer hope for improved outcomes in lung cancer patients 3Early detection techniques offer hope for improved outcomes in lung cancer patients 4Advances in personalized medicine for lung cancer 2Advances in personalized medicine for lung cancer 3Advances in personalized medicine for lung cancer 4Advances in personalized medicine for lung cancer 5New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 2New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 3
...
... Edited by R. Edwards ... on all types of immunoassays, ... surface immunoassays and on the ... immunoassays. Essential information is also ...
ANTI S. ENTERID LPS...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: